MYRF-AS1

Across TCGA pan-cancer cohorts, MYRF-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of MYRF-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MYRF-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MYRF-AS1 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, KICH, and COAD are the cancer types where MYRF-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYRF-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.155	<.001	8	view →
KICH	Male	II,III,IV	−0.131	<.001	8	view →
COAD	All	All	+0.220	<.001	6	view →
STAD	All	All	+0.351	<.001	4	view →
READ	All	All	+0.128	.037	4	view →
LUSC	Female	All	−0.037	.003	4	view →
KIRP	All	All	+0.109	.028	1	view →
LIHC	All	All	+0.089	.036	1	view →
BLCA	All	III,IV	+0.021	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

MYRF-AS1–KIRC

Open the KIRC breakdown →